Investors & Media

Company Profile
We are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
Recent Press ReleasesMore >>
DateTitle 
01/13/17New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
Primary Endpoint from End of Study Analysis Presented at British Paediatric Neurology Association Annual Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA™ (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent ventilation in SPINRAZA-treated infants with spinal muscular atrophy (SMA) compared to untreated infants. The data were prese... 
Download PDF
01/06/17Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance
Strong financial performance resulting from the continued success of pipeline programs CARLSBAD, Calif., Jan. 6, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the Company expects to significantly improve upon its 2016 financial guidance.  Ionis expects to end 2016 with pro forma net operating income in the low to mid $20 million range and more than $650 million in cash.  The Company's significantly improved financial guidance is the result of numerous ac... 
 
01/06/17Ionis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
- Collaboration with Novartis provides near-term payments of $225 million plus potential license fees, milestone and royalty payments - Akcea retains rights to co-commercialize to lipid specialists - Deal valued at significantly over $1 billion if both drugs are licensed and successfully commercialized - Company to host conference call at 9:30 a.m. Eastern Time CARLSBAD, Calif. and CAMBRIDGE, Mass., Jan. 6, 2017 /PRNewswire/ -- Ionis Pharmaceuticals Inc. (NASDAQ: IONS) and Akcea Ther... 
 
01/04/17Ionis Pharmaceuticals Reports Positive Data from Phase 2 Study of IONIS-GCGR Rx in Patients with Type 2 Diabetes
- Company to present top-line results at Pipeline Update Webcast on January 5 - CARLSBAD, Calif., Jan. 4, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive data from a Phase 2 study of IONIS-GCGRRx in 79 patients with type 2 diabetes.  In this study, patients with type 2 diabetes uncontrolled on stable, maximal metformin therapy treated with IONIS-GCGRRx achieved robust and sustained, statistically significant improvements in hemoglobin A1c (HbA1c) and ... 
 
Upcoming EventsMore >>
There are currently no events scheduled.

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Data provided by Nasdaq. Minimum 15 minutes delayed.